Business briefs: Sobi and Savient; Novartis; Saatchi & Saatchi Wellness

Share this article:

Sobi and Savient Pharmaceuticals inked a co-promote agreement for RA drug Kineret in the US. Savient's sales organization details US rheumatologists for gout drug Krystexxa. “The collaboration will expand our reach to US physicians who treat patients suffering from rheumatoid arthritis and augment our own ability to directly support the pediatric community,” said Sobi chief operating officer Alan Raffensperger. The agreement grants Savient exclusive rights to co-promote the drug with Sobi in the US starting in April. Sobi retains responsibility for manufacturing, supply, safety and regulatory activities. 

FDA approved Novartis' Zortress for prevention of organ rejection in adult liver transplant patients. The mTOR inhibitor is already approved for kidney transplants in the US, and was approved by European health authorities for adult liver transplants under the brand name Certican in Q4. It's the first new drug in over a decade approved by FDA for prevention of organ rejection in adult liver transplant patients.

Saatchi & Saatchi Wellness named Kathy Delaney chief creative officer. Delaney, who also becomes global chief creative officer of the Saatchi & Saatchi Health network, joins from her own consultancy, which launched the SK Energy Shots brand in partnership with Pure Growth Partners. From 2007 to 2011, she served as chief creative officer and president of digital botique Nitro until its sale to Sapient. She succeeds Helayne Spivak, who left Saatchi & Saatchi Wellness in August to Virginia Commonwealth University's VCU Brandcenter.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.